Bonum Therapeutics, Inc.
5 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- $26.9Msold on Form D
Filed a Form D on 3 Apr 2026: $26.9M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
A company that just raised has fresh capital, a new board and new vendors to choose.
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 8 directorsboard
8 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
Financing history
- Apr 3, 2026Form D equity offering · $26.9M (form d sold) · 8 investorsFact Form D · “Bonum Therapeutics, Inc. filed Form D: $26,907,396 sold of $32,301,381, Biotechnology”
Investors on record
- Samsara Biocapital, LLC board only, Mitchell Mutz (strongly supported) Inference sec.gov
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.No firm portfolio page lists this company, so no outcome is stated.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Diane Hollenbaugh Executive Officer sec.gov
- John Mulligan Executive Officer/Director/Promoter sec.gov
- Neela Patel Executive Officer sec.gov
- Samuel Bjork Director Fact
- Monique Schiersing Director Fact
Show all 6 officers and directors
- Diane Hollenbaugh Executive Officer sec.gov
- John Mulligan Executive Officer/Director/Promoter sec.gov
- Neela Patel Executive Officer sec.gov
- Samuel Bjork Director Fact
- Monique Schiersing Director Fact
- John Mckearn Director Fact
Timeline
- Apr 17, 2026Bonum Therapeutics, Inc. filed Form D: $26,907,396 sold of $32,301,381, BiotechnologyForm D filed Fact Form D
Evidence
Every observation on this company
- Entity type: Corporation Apr 17, 2026 Fact Form D
- Form D industry group: Biotechnology Apr 17, 2026 Fact Form D
- Amendment: false Apr 17, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Apr 17, 2026 Fact Form D
- Incorporated: withinFiveYears Apr 17, 2026 Fact Form D
- Jurisdiction: Delaware Apr 17, 2026 Fact Form D
- Amount sold (Form D): $26.9M Apr 17, 2026 Fact Form D
- Offering amount (Form D): $32.3M Apr 17, 2026 Fact Form D
- Exemptions: 06b Apr 17, 2026 Fact Form D
- First sale: 2026-04-03 Apr 17, 2026 Fact Form D
- Investors (Form D): 8 Apr 17, 2026 Fact Form D
- Minimum investment (Form D): 0 Apr 17, 2026 Fact Form D
- Securities offered: equity Apr 17, 2026 Fact Form D
- Office address: Apr 17, 2026 Fact Form D
- Year of incorporation: 2021 Apr 17, 2026 Fact Form D
Record history
- Form D filed2026-04-17source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.